Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs.

Our focus is the metabolic space (e.g. obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics.

Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise.

We work with some of the most interesting and loyal partners and customers from across the world in the pharmaceutical and biotech industry as well as academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

Biotechnology

Gubra

Henrik Blou

Jacob Tórsheim Voltelen

Niels Vrang

Trine Nygaard Hamann

Kristoffer Rigbolt

Kristian Borbos

Helle Kirstein Erichsen

The Research & Development team at Gubra is dedicated to advancing the company's proprietary early target and drug discovery programs, with a strong focus on metabolic diseases such as obesity, diabetes, NASH, and gastrointestinal disorders. This multidisciplinary team, including experts in pharmacology, computational biology, chemistry, bioanalysis, and imaging, works collaboratively to design and execute high-quality research projects. They leverage state-of-the-art techniques in peptide chemistry, in vivo and ex vivo assays, molecular pharmacology, and bioinformatics to drive scientific innovation and support the development of novel therapeutics.

Research & Development

Research and Scientific Development

Leadership Team

Research & Development

About

Team members

Other teams at Gubra

Research and Scientific Development

Leadership Team